Head-to-head evidence
Lamotrigine vs Oxcarbazepine (Trileptal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Lamotrigine
Marketed by GlaxoSmithKline
NCT01431976 · Phase 3 · completed
This was a small, single-arm, open-label study of 20 participants, with no randomization, blinding, or comparator. The primary clinical endpoint found 7 of 20 participants (35%) seizure free by hyperventilation-EEG at the end of maintenance, but there was no formal between-group comparison.
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00050934 · Phase 3 · completed
The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lamotrigine's landscape · Oxcarbazepine (Trileptal)'s landscape